Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCB Insights

The top 50 Latin America venture investors in 2026

View original at cbinsights.com
CB Insights - Enterprise Ai Title: The top 50 Latin America venture investors in 2026 Date: 2026-03-03 22:26 Source: https://www.cbinsights.com/research/the-top-50-latin-america-venture-investors/ <p><span style="font-weight: 400;">Latin America’s venture market is pulling back: deal volume has fallen by </span><a href…
Opening lines of the source · CB Insights · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Chile's 4 top-ranked VCs average just 9 years old

    80% confidence

  • With the majority of LatAm businesses being resource-constrained SMEs, AI tools help companies scale without adding headcount

    80% confidence

  • Brazil's top VCs kept 77% of their deals domestic, insulating local startups from cross-border capital slowdown

    80% confidence

  • Brazilian startups captured 60% of all deals from the region's top 50 investors

    80% confidence

  • Sales and customer service applications account for 35% of AI bets by top 3 LatAm VCs

    80% confidence

  • Fintech is emerging as the strongest contributor to LatAm's highest-quality venture portfolios

    80% confidence

  • LatAm's top investors are all-in on AI for sales and customer service, with top 3 VCs directing a quarter of their deals since 2023 to AI companies

    80% confidence

  • FCJ Venture Builder portfolio companies show 36% average M&A probability versus 21.6% global average

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com